Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
Jeffrey S. Weber(NYU Langone Health), Georgina V. Long(The University of Sydney), Luis de la Cruz‐Merino, Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Daniel J. Tenney(Bristol-Myers Squibb (Germany)), Michael P. Brown(South Australia Pathology), Alexander M. Menzies(The University of Sydney), Jacob Schachter, Michael Schenker(Sorbonne Université), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(National Center for Tumor Diseases), Jacopo Pigozzo(Istituto Oncologico Veneto), Thomas Eigentler(University Children's Hospital Tübingen), Eva Muñoz‐Couselo(Vall d'Hebron Hospital Universitari), Veerle de Pril(Inserm), Jean‐Jacques Grob(Aix-Marseille Université), Shahneen Sandhu(The University of Melbourne), Julia Braverman(Bristol-Myers Squibb (United States)), Jessica C. Hassel(German Cancer Research Center), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Paola Queirolo, Stéphane Dalle(Hospices Civils de Lyon), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), James Larkin(Trinity College Dublin), André van der Westhuizen(Hunter Medical Research Institute), Matteo S. Carlino(The University of Sydney), Andrew Haydon(The Alfred Hospital), Helen Gogas(National and Kapodistrian University of Athens), Hao Tang(Hainan University), Caroline Robert(Institut Gustave Roussy), Tuba Öcek Baş(Bristol-Myers Squibb (United States)), Anna Maria Di Giacomo(University of Siena), Victoria Atkinson(Greenslopes Private Hospital), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Sandra Re(Bristol-Myers Squibb (United States)), Marcus O. Butler(University of Toronto)
Cited by 166
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k